Perceptive Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Perceptive Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-1,600,000	Closed	-$35.7M	–	166
2014 Q4	$35.7M	Buy	1,600,000 +947,000	+145%	+$17.9M	3%	6
2014 Q3	$10.2M	Buy	+653,000	New	+$9.76M	1.04%	26
2013 Q4	–	Sell	-289,500	Closed	-$3.28M	–	128
2013 Q3	$3.28M	Buy	+289,500	New	+$3.98M	0.27%	50
2013 Q2	–	Hold	0	–	–	–	39

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Perceptive Advisors's NBIX Position: Q1 2026 in Review

Perceptive Advisors reduced its Neurocrine Biosciences (NBIX) stake by 80% in Q1 2026, selling an estimated $35.3M and leaving 65,050 shares worth $8.57M. The position accounts for 0.17% of the portfolio, ranked #68.

Perceptive Advisors first reported a position in NBIX in Q2 2013 and has held it in 52 quarters since. The position peaked at $587M in Q3 2018. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Perceptive Advisors held 65,050 shares of Neurocrine Biosciences worth $8.57M as of Q1 2026.
Perceptive Advisors sold 266,000 Neurocrine Biosciences shares in Q1 2026, an estimated $35.3M.
Neurocrine Biosciences made up 0.17% of Perceptive Advisors's portfolio in Q1 2026, its #68 holding.
Perceptive Advisors first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 52 quarters since.
Perceptive Advisors's Neurocrine Biosciences position peaked at $587M in Q3 2018.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.